The functional mechanism of simvastatin in experimental osteoporosis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Du Z, Chen J, Yan F, Xiao Y (2009) Effects of simvastatin on bone healing around titanium implants in osteoporotic rats. Clin Oral Implants Res 20:145–150
Lasota A, Danowska-Klonowska D (2004) Experimental osteoporosis–different methods of ovariectomy in female white rats. Rocz Akad Med Bialymst 49(Suppl 1):129–131
Shirke SS, Jadhav SR, Jagtap AG (2008) Methanolic extract of Cuminum cyminum inhibits ovariectomy-induced bone loss in rats. Exp Biol Med (Maywood) 233:1403–1410
Canalis E, Giustina A, Bilezikian JP (2007) Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905–916
Grey A, Reid IR (2005) Emerging and potential therapies for osteoporosis. Expert Opin Investig Drugs 14:265–278
Lane NE, Kelman A (2003) A review of anabolic therapies for osteoporosis. Arthritis Res Ther 5:214–222
Dominguez LJ, Scalisi R, Barbagallo M (2010) Therapeutic options in osteoporosis. Acta Biomed 81(Suppl 1):55–65
Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R et al (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288:334–341
Reginster JY, Sarlet N (2006) The treatment of severe postmenopausal osteoporosis: a review of current and emerging therapeutic options. Treat Endocrinol 5:15–23
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333
Salari Sharif P, Abdollahi M, Larijani B (2011) Current, new and future treatments of osteoporosis. Rheumatol Int 31:289–300
Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205–3210
Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211–3216
Mundy G, Garrett R, Harris S, Chan J, Chen D et al (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946–1949
Emmanuele L, Ortmann J, Doerflinger T, Traupe T, Barton M (2003) Lovastatin stimulates human vascular smooth muscle cell expression of bone morphogenetic protein-2, a potent inhibitor of low-density lipoprotein-stimulated cell growth. Biochem Biophys Res Commun 302:67–72
Hatano H, Maruo A, Bolander ME, Sarkar G (2003) Statin stimulates bone morphogenetic protein-2, aggrecan, and type 2 collagen gene expression and proteoglycan synthesis in rat chondrocytes. J Orthop Sci 8:842–848
Song C, Guo Z, Ma Q, Chen Z, Liu Z et al (2003) Simvastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells. Biochem Biophys Res Commun 308:458–462
Sugiyama M, Kodama T, Konishi K, Abe K, Asami S et al (2000) Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells. Biochem Biophys Res Commun 271:688–692
Izumo N, Fujita T, Nakamuta H, Koida M (2001) Lipophilic statins can be osteogenic by promoting osteoblastic calcification in a Cbfa1- and BMP-2-independent manner. Methods Find Exp Clin Pharmacol 23:389–394
Li X, Cui Q, Kao C, Wang GJ, Balian G (2003) Lovastatin inhibits adipogenic and stimulates osteogenic differentiation by suppressing PPARgamma2 and increasing Cbfa1/Runx2 expression in bone marrow mesenchymal cell cultures. Bone 33:652–659
Wong RW, Rabie AB (2005) Early healing pattern of statin-induced osteogenesis. Br J Oral Maxillofac Surg 43:46–50
Alam S, Ueki K, Nakagawa K, Marukawa K, Hashiba Y et al (2009) Statin-induced bone morphogenetic protein (BMP) 2 expression during bone regeneration: an immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107:22–29
Rizzo M, Rini GB (2006) Statins, fracture risk, and bone remodeling: what is true? Am J Med Sci 332:55–60
Castaneda S, Largo R, Calvo E, Rodriguez-Salvanes F, Marcos ME et al (2006) Bone mineral measurements of subchondral and trabecular bone in healthy and osteoporotic rabbits. Skelet Radiol 35:34–41
Li GW, Tang GY, Liu Y, Tang RB, Peng YF et al (2012) MR spectroscopy and micro-CT in evaluation of osteoporosis model in rabbits: comparison with histopathology. Eur Radiol 22:923–929
Arens AM, Barr B, Puchalski SM, Poppenga R, Kulin RM et al (2011) Osteoporosis associated with pulmonary silicosis in an equine bone fragility syndrome. Vet Pathol 48:593–615
Zhang Y, Yu L, Ao M, Jin W (2006) Effect of ethanol extract of Lepidium meyenii Walp. on osteoporosis in ovariectomized rat. J Ethnopharmacol 105:274–279
Scholz-Ahrens KE, Delling G, Stampa B, Helfenstein A, Hahne HJ et al (2007) Glucocorticosteroid-induced osteoporosis in adult primiparous Gottingen miniature pigs: effects on bone mineral and mineral metabolism. Am J Physiol Endocrinol Metab 293:E385–E395
Liu X, Lei W, Wu Z, Cui Y, Han B et al (2012) Effects of glucocorticoid on BMD, micro-architecture and biomechanics of cancellous and cortical bone mass in OVX rabbits. Med Eng Phys 34:2–8
Baofeng L, Zhi Y, Bei C, Guolin M, Qingshui Y et al (2010) Characterization of a rabbit osteoporosis model induced by ovariectomy and glucocorticoid. Acta Orthop 81:396–401
Schorlemmer S, Ignatius A, Claes L, Augat P (2005) Inhibition of cortical and cancellous bone formation in glucocorticoid-treated OVX sheep. Bone 37:491–496
Akhter MP, Cullen DM, Gong G, Recker RR (2001) Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice. Bone 29:121–125
Chen H, Wu M, Kubo KY (2012) Combined treatment with a traditional Chinese medicine, Hachimi-jio-gan (Ba-Wei-Di-Huang-Wan) and alendronate improves bone microstructure in ovariectomized rats. J Ethnopharmacol 142:80–85
Hordon LD, Itoda M, Shore PA, Shore RC, Heald M et al (2006) Preservation of thoracic spine microarchitecture by alendronate: comparison of histology and microCT. Bone 38:444–449
Zhao FD, Pollintine P, Hole BD, Adams MA, Dolan P (2009) Vertebral fractures usually affect the cranial endplate because it is thinner and supported by less-dense trabecular bone. Bone 44:372–379
Li L, Zeng Z, Cai G (2011) Comparison of neoeriocitrin and naringin on proliferation and osteogenic differentiation in MC3T3-E1. Phytomedicine 18:985–989
Chen PY, Sun JS, Tsuang YH, Chen MH, Weng PW et al (2010) Simvastatin promotes osteoblast viability and differentiation via Ras/Smad/Erk/BMP-2 signaling pathway. Nutr Res 30:191–199
Ho ML, Chen YH, Liao HJ, Chen CH, Hung SH et al (2009) Simvastatin increases osteoblasts and osteogenic proteins in ovariectomized rats. Eur J Clin Invest 39:296–303
Oxlund H, Andreassen TT (2004) Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone 34:609–618
Yin H, Shi ZG, Yu YS, Hu J, Wang R et al (2012) Protection against osteoporosis by statins is linked to a reduction of oxidative stress and restoration of nitricoxide formation in aged and ovariectomized rats. Eur J Pharmacol 674:200–206
Baek KH, Lee WY, Oh KW, Tae HJ, Lee JM et al (2005) The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells. J Korean Med Sci 20:438–444
Hwang R, Lee EJ, Kim MH, Li SZ, Jin YJ et al (2004) Calcyclin, a Ca2+ ion-binding protein, contributes to the anabolic effects of simvastatinon bone. J Biol Chem 279:21239–21247
Maeda T, Matsunuma A, Kawane T, Horiuchi N (2001) Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1cells. Biochem Biophys Res Commun 280:874–877
von Stechow D, Fish S, Yahalom D, Bab I, Chorev M et al (2003) Does simvastatin stimulate bone formation in vivo? BMC Musculoskelet Disord 4:8
Yazawa H, Zimmermann B, Asami Y, Bernimoulin JP (2005) Simvastatin promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells. J Periodontol 76:295–302
Chuang SC, Liao HJ, Li CJ, Wang GJ, Chang JK et al (2013) Simvastatin enhances human osteoblast proliferation involved in mitochondrial energy generation. Eur J Pharmacol 714:74–82
Phimphilai M, Zhao Z, Boules H, Roca H, Franceschi RT (2006) BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype. J Bone Miner Res 21:637–646
Lee MH, Kim YJ, Kim HJ, Park HD, Kang AR et al (2003) BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 278:34387–34394
Kim T, Ha H, Shim KS, Cho WK, Ma JY (2013) The anti-osteoporotic effect of Yijung-tang in an ovariectomized rat model mediated by inhibition of osteoclast differentiation. J Ethnopharmacol 146:83–89
Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H et al (2004) Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J Cell Biochem 92:458–471